Thinking and memory in chronic ITP
Part of Blood & lymphatic, Immune system & allergy, Mental health clinical trials.
This study looks at whether chronic or persistent immune thrombocytopenia (ITP) affects thinking and memory. If you have had low platelet counts for 3 months or more and have been treated for ITP, you may help researchers understand how the condition can impact the brain.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with chronic or persistent ITP, meaning your platelets have been low (under 50) for at least 3 months.
- You have been treated with at least one ITP therapy, such as steroids, IVIG, or a thrombopoietin receptor agonist.
- You can follow instructions in English.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study looks at blood and immune system patterns in adults with primary immune thrombocytopenia (ITP) who are starting their first treatment. The goal is to better understand what’s happening in ITP, which may improve how future patients are cared for.
This study tests whether a drug called hetrombopag can help your immune system stop attacking your platelets, so your platelet count stays up even after stopping the drug. It's for people with ITP who responded well to hetrombopag but want to see if they can stay in remission without it.
This study looks at how doctors treat immune thrombocytopenia (ITP)—a blood condition where your body attacks its own platelets—using a drug called eltrombopag. Researchers want to understand treatment patterns and outcomes in real-world practice to improve care.
This trial looks at whether certain proteins in the blood can help doctors diagnose immune thrombocytopenia (ITP), a condition where your immune system destroys platelets. It may help find a faster, simpler way to confirm ITP.
This study looks back at medical records of people with newly diagnosed or persistent ITP (lasting up to 12 months) to understand how the condition is treated in real life. Anyone who received standard ITP treatments or none at all may be included.
This study looks at people who survived immune-mediated thrombotic thrombocytopenic purpura (iTTP) to see how early treatment (plasma exchange and a medicine called caplacizumab) affects long-term brain health and thinking skills. It involves an MRI scan and thinking tests to understand recovery after iTTP.
Hear when a new Immune Thrombocytopenia trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.